AI Article Synopsis
Article Abstract
Background & Aims: Data on the differences in ethnicity and race among patients with primary biliary cholangitis (PBC) awaiting liver transplantation (LT) are limited. We evaluated liver transplant waitlist trends and outcomes based on ethnicity and race in patients with PBC in the United States.
Methods: Using the United Network for Organ Sharing (UNOS) registry, we collected data on patients with PBC on the liver transplant waitlist, and performed analysis with a focus on ethnicity and race-based variations clinical manifestations, waitlist mortality and LT rates from 2000 to 2014. Outcomes were adjusted for demographics, complications of portal hypertension, and Model for End-stage Liver Disease score at time of waitlist registration.
Results: Although the number of white PBC waitlist registrants and additions decreased from 2000 to 2014, there were no significant changes in the number of Hispanic PBC waitlist registrants and additions each year. The proportion of Hispanic patients with PBC on the liver transplant waitlist increased from 10.7% in 2000 to 19.3% in 2014. Hispanics had the highest percentage of waitlist deaths (20.8%) of any ethnicity or race evaluated. After adjusting for demographic and clinical characteristics, Hispanic patients with PBC had the lowest overall rate for undergoing LT (adjusted hazard ratio, 0.71; 95% CI, 0. 60-0.83; P < .001) and a significantly higher risk of death while on the waitlist, compared to whites (adjusted hazard ratio, 1.41; 95% CI, 1.15-1.74; P < .001). Furthermore, Hispanic patients with PBC had the highest proportion of waitlist removals due to clinical deterioration.
Conclusions: In an analysis of data from UNOS registry focusing on outcomes, we observed differences in rates of LT and liver transplant waitlist mortality of Hispanic patients compared with white patients with PBC. Further studies are needed to improve our understanding of ethnicity and race-based differences in progression of PBC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331901 | PMC |
| http://dx.doi.org/10.1016/j.cgh.2017.12.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Biliary Cholangitis: personalizing second-line therapies.
Hepatology
November 2024
Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.
Article Synopsis
- Primary biliary cholangitis (PBC) is an autoimmune disease primarily affecting middle-aged women, characterized by damage to small bile ducts, leading to liver issues like cholestasis and cirrhosis.
- The main treatment for PBC has been ursodeoxycholic acid, which helps slow disease progression but doesn't alleviate symptoms; new second-line therapies are being developed for patients who don't respond well.
- Recent medications like obeticholic acid, elafibranor, and seladelpar show promise in improving liver function and reducing cholestasis, while considerations for personalized treatment based on patient features are essential.
Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.
Am J Surg Pathol
December 2024
Department of Liver Research Center, Beijing Friendship Hospital, Capital Medical University; National Clinical Research Center for Digestive Diseases, Beijing, China.
Article Synopsis
- The study focuses on early-stage primary biliary cholangitis (PBC) with a rare condition known as ductopenia, which involves significant bile duct loss without major liver damage.
- Researchers analyzed data from 141 PBC patients over 4.5 years, finding that those with ductopenia had notably higher levels of liver enzymes and cholesterol but a poorer response to standard treatments compared to those without ductopenia.
- High baseline cholesterol levels were identified as a key predictor for ductopenia in early-stage PBC patients, indicating a potential risk factor for adverse health outcomes.
Petrous bone cholesteatoma (PBC): report of 94 cases of PBC with focus on intraoperative endoscopic assistance, and systematic review of the literature.
Eur Arch Otorhinolaryngol
December 2024
Department of Otolaryngology-Head and Neck Surgery, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo, 46. 3rd Floor, 28007, Madrid, CP, Spain.
Purpose: The aim of this study is to assess the clinical characteristics, classification, surgical approaches, interventional strategies, and treatment outcomes of patients with petrous bone cholesteatoma (PBC).
Methods: Observational retrospective study of patients with PBC managed by the senior author of this paper between 1995 and 2024 in a tertiary referral center. A literature review was made, identifying 16 articles.
Mean liver density independently predicts therapeutic response and liver-related mortality in patients with primary biliary cholangitis.
Quant Imaging Med Surg
December 2024
Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
Background: Sarcopenia, myosteatosis, and sarcopenic obesity are known to adversely affect nutritional status and quality of life in cirrhotic patients. However, there is limited research on these conditions in individuals with primary biliary cholangitis (PBC). This study aims to identify risk factors for sarcopenia, myosteatosis, and sarcopenic obesity in PBC patients and to investigate their association with therapeutic outcomes and liver-related mortality.
View Article and Find Full Text PDFNatural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study.
J Gastroenterol Hepatol
December 2024
Department of Hepatology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
Background And Aim: Prognosis in autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) has historically been poor. This multicenter retrospective cohort study investigated the natural history and assessed the predictors of outcomes in patients with AIH, PBC, and PSC.
Methods: AIH, PBC, and PSC patients were identified from the state-wide Hepascore and Clinical Outcome cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!